Cholangiocarcinoma Trial – Learn about a phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma (bile duct cancer) with pembrolizumab and Sylatron (peginterferon alfa-2b): HCRN GI16-263…


Shared Information improves and Galvanises our Outcomes
What do you think about this video ? can you recommend a video? We welcome your comments?